Kairos Pharma CEO John Yu joined Steve Darling from Proactive to share major updates on the company’s latest cancer research developments. A significant milestone in its academic partnership with Cedars-Sinai Medical Center has been achieved, as Cedars-Sinai secured $600,000 in funding from the Department of Defense’s Lung Cancer Research Program. This grant will accelerate work on an innovative therapy designed to address chemotherapy resistance and cachexia—a severe condition causing muscle loss and weight depletion in cancer patients. The funding will support efforts to develop a first-in-class treatment aimed at counteracting muscle atrophy, improving physical strength, and enhancing the effectiveness of existing cancer therapies. By targeting key biological pathways linked to cachexia, this therapy could provide much-needed support for cancer patients striving to maintain their health and resilience throughout treatment. In a further expansion of its clinical initiatives, Kairos Pharma has added the prestigious Huntsman Cancer Institute in Salt Lake City, Utah, as a new site for its ongoing Phase 2 clinical trial evaluating an advanced antibody therapy for castrate-resistant prostate cancer. This trial, backed by both Kairos Pharma and a grant from the National Cancer Institute, is assessing whether the therapy can overcome treatment resistance by targeting a key protein involved in disease relapse. With continued progress in both research and clinical trials, Kairos Pharma is reinforcing its commitment to pioneering new approaches in cancer treatment, offering hope to patients facing some of the most challenging forms of the disease. #proactiveinvestors #kairospharmalitd #nyseamerican #kapa #cancer #env105 #CancerResearch #ProstateCancer #LungCancer #ClinicalTrials #Biotech #Immunotherapy #Healthcare #PharmaInnovation #DrugDevelopment